Overview

A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Status:
Unknown status

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

purpose Primary endpoint - To evaluate the 24 month disease free survival Second endpoints - To evaluate the 24 month overall survival To analyze the toxicity and the quality of life

Phase:

Phase 2

Details

Lead Sponsor:

Korean Gynecologic Oncology Group

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Gemcitabine
Paclitaxel